Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
Tea with the IRB:“Tips When Submitting to the IRB”
Rocio Yong, M.P.H., C.I.P. 2/25/2020
Introductions
• Department / Division• Research Role• Submissions to HSPP• Previous role before you
joined CHLA
2
#1 Obtain Human Subjects Certification
• Step 1 – Complete one or both of the CITI Program Human Research Basic
Courses (Biomedical or Social/Behavioral)
3
#1 Obtain Human Subjects Certification
• If research is considered more than minimal risk, also complete Basic Good Clinical Practice (GCP) Courses (GCP and GCP - Social and Behavioral Research Best Practices for Clinical Research)
• Access CITI at www.citiprogram.org
4
#2 iStar Application – Answer All Questions
• Describe what you want to do. For example:– We are seeking IRB approval for…– We are interested in…– This research will look at…
• In #12.1 - Include a description of the research procedures and the routine clinical care procedures– To evaluate risks and benefits, the IRB needs to consider those risks
and benefits that may result from the research (as distinguished from risks and benefits of therapies subjects would receive even if not participating in the research)
• Reference the Study Protocol (e.g. See Section X of the Study Protocol) whenever possible
5
#2 iStar Application – Answer All Questions
• If not applicable #22d.4 (study instructions) and #22d.5 (instruments) may be left blank
6
#2 iStar Application – Answer All Questions
• If the research does not involve greater than minimal risk skip #25.3 or click “Other” and enter “Not applicable” in #25.3.1
7
#3 iStar Application – Upload Study Documents
• Submit– Study Protocol– CRFs, REDCap Forms, Data Collection Forms– Instruments, Surveys – Focus Group Guides– Recruitment Materials – Consent and Assent Forms
• Submit translated Consent and Assent Forms only• Use a template Study Protocol from the HSPP website (new –
coming soon)
8
#3 iStar Application – Upload Study Documents
• Submit FDA regulatory status of drug or device– Documentation that includes IND#
• Sponsor protocol imprinted with the IND#• Written documentation from the sponsor documenting IND#• Written communication from the FDA documenting the IND#
(required if the investigator holds the IND)– Revised Investigator Brochure (IB) must be submitted by the
investigator
• Submit IDE – Documentation that includes IDE#
9
#3 iStar Application – Upload Study Documents
• Submit device information– Premarket Approval (PMA) (https://www.fda.gov/home)– 510(k) (https://www.fda.gov/home)– Non Significant Risk – PI Documentation– Device Brochure
10
#3 iStar Application – Upload Study Documents
• Premarket Approval (PMA) Database
11
#3 iStar Application – Upload Study Documents
• 510(k) Premarket Notification Database
12
#3 iStar Application – Upload Study Documents
• Non Significant Risk – PI Documentation
13
#4 Submit to IRB
• Applications in Pre Submission and an APP# have not been received by the HSPP
14
#5 Contact the iStar Helpdesk
• If your application is in Department or Division review for extended amounts of time
• If you have not received an “Agree to Participate” notice• If you receive an error message
15
#6 Answer Communications
• Address comments requesting clarifications, reconciling of discrepancies, requests for additional information
• Review edits and acknowledge these (if accurate)
• If edits are not accurate revise these and provide an explanation
16
#7 Not Sure How to Address Something
IRB Administrator Email Ext #
Mara [email protected] 1‐7031
Dongqing [email protected] 1‐6023
Maryann [email protected] 1‐4010
Jeremiah [email protected] 1‐4224
Linda [email protected] 1‐8171
Deebra [email protected] 1‐2080
Rocio [email protected] 1‐8317
Skyler [email protected] 1‐7627
17
#8 Amendments• Provide description and rationale for proposed changes• Avoid emailing documents to IRB Administrators to review• “Upload Revision” function has become “…”
18
#8 Continuing Review
• Submit continuing review applications with sufficient time for review. The recommended (per the IRB approval memo) is at least 8 weeks before the expiration date
• Do not let research expire
19
#10 Ceded Submissions
• For Ceded review access the “Investigator Guidance” section in the Human Subjects Protection Program intranet space
• For IRB reliance agreement questions email [email protected]
20
A Few More Things
• Edit Personnel function should only be used when consenting privileges do not need to be designated.
• Edit Personnel function can be used to remove study personnel (except Principal Investigator)
• Review the Approval Letter• Close the study once the research is completed
21
QUESTIONSCOMMENTSSCENARIOS
22